Welcome to our dedicated page for Baxter Intl SEC filings (Ticker: BAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Baxter International's SEC filings reveal the operational complexity behind one of the world's major medical products manufacturers. The company's 10-K annual reports detail three distinct business segments—medication delivery, renal care, and clinical nutrition—each with different revenue drivers, regulatory challenges, and competitive dynamics. Understanding which segment drives growth and profitability requires digging into financial footnotes that break down performance by geography and product line.
For investors tracking Baxter, quarterly 10-Q filings disclose segment-level revenue trends, manufacturing disruptions, and regulatory compliance matters that affect product availability. The medical device industry faces unique disclosure requirements around product recalls, FDA warning letters, and manufacturing facility inspections. Baxter's 8-K filings capture material events such as supply agreements with hospital systems, changes in manufacturing capacity, and developments in product liability matters. Our AI highlights these critical disclosures instantly, saving hours of manual document review.
Form 4 insider transaction filings track when Baxter executives and directors buy or sell shares, providing insight into management's confidence in the business. The company's DEF 14A proxy statements detail executive compensation structures, including how leadership incentives align with performance metrics like revenue growth, operating margins, and new product approvals. Access real-time filing updates from EDGAR with AI-powered summaries that explain what each document means for your investment analysis.
Baxter International Inc. filed an 8-K announcing it furnished an earnings press release for the period ended September 30, 2025. The press release is attached as Exhibit 99.1. The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed filed under the Exchange Act. Exhibits also include the Cover Page Interactive Data File as Exhibit 104.
Baxter International (BAX) announced a leadership change. Heather Knight will resign as Executive Vice President, Chief Operating Officer, and interim group president of Medical Products and Therapies (MPT) effective October 29, 2025, to join a company in the healthcare industry.
On the transition date, President and CEO Andrew Hider will also serve as interim group president of MPT, and Baxter will eliminate the COO role. This consolidates operational oversight under the CEO while the company manages the MPT leadership transition.
BlackRock Portfolio Management LLC filed a Schedule 13G/A reporting beneficial ownership of 39,204,985 shares (7.6%) of Baxter International (BAX)
The filer reports 38,736,192 shares with sole voting power and 39,204,985 shares with sole dispositive power. The certification states the securities were acquired and are held in the ordinary course and not to change or influence control.
Alok Sonig, EVP & Group President, Pharma at Baxter International (BAX), reported a transaction on 09/02/2025. He relinquished 3,191 shares of Baxter common stock at a price of $24.17 per share to cover tax withholding tied to the delivery of vested restricted stock units granted on 09/01/2022. After the transaction, the reporting person beneficially owns 128,219 shares, which the filing notes includes automatic dividend reinvestment. The sale was reported on a Form 4 signed by an attorney-in-fact on 09/04/2025.
Andrew P. Hider, President and CEO and Director of Baxter International Inc. (BAX), reported issuance of equity awards on 09/02/2025. He received 236,237 restricted stock units (RSUs) as a make-whole award for unvested prior employer equity and 131,813 RSUs as a pro rata 2025 annual grant, bringing his total reported common stock beneficial ownership to 368,050 shares after the transactions. He also received stock options covering 465,651 shares with a $24.17 exercise price, exercisable in three equal annual installments beginning 09/02/2026 and expiring 09/02/2035. The RSUs vest in three equal annual installments starting 09/02/2026, with accelerated vesting on certain termination events. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Joel T. Grade, EVP and CFO of Baxter International Inc. (BAX), reported a grant of 102,712 restricted stock units (RSUs) on 09/02/2025 that will vest on 09/05/2028, subject to the Amended and Restated Baxter International Inc. 2021 Incentive Plan vesting conditions. The RSUs will vest immediately if the reporting person’s employment is terminated without Cause as defined in the plan. After the reported transaction, the filing shows 222,560 shares beneficially owned, which includes automatic dividend reinvestment and shares held in Baxter’s Employee Stock Plan. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Baxter International (BAX) insider James W. Borzi, EVP and Chief Supply Chain Officer, reported a disposition of 1,848 shares on 09/02/2025 at $24.17 per share. The filing explains these shares were forfeited to cover tax withholding related to vested restricted stock units that settled on 09/02/2025 from an award granted 09/01/2023. After the transaction, Borzi beneficially owns 71,948 shares, which includes automatic dividend reinvestment. The Form 4 was signed by an attorney-in-fact on behalf of Borzi on 09/04/2025.
Pzena Investment Management, LLC reports beneficial ownership of 55,458,217 shares of Baxter International Inc. common stock, representing 10.8% of the class. The filing shows Pzena has sole voting power over 46,921,845 shares and sole dispositive power over 55,458,217 shares. The statement notes these shares are held for clients of the investment manager and that no single client accounts for more than 5% of the class. The filing identifies Baxter's principal executive offices at One Baxter Parkway, Deerfield, Illinois, and lists Pzena's address at 320 Park Avenue, New York. The Schedule 13G/A was signed by Steven Coffey, Chief Legal Risk Officer & Chief Compliance Officer, on 09/02/2025.
Andrew P. Hider filed a Form 3 for Baxter International Inc. (BAX) reporting his relationship to the issuer as Director and President and CEO. The Form 3 reports 0 shares of Baxter common stock beneficially owned as of the 08/19/2025 event date. The filing was signed by attorney in-fact Ellen K. Bradford on 08/25/2025.
Brent Shafer, Chair of Baxter International's Board, reported a transaction on 08/19/2025 involving company common stock. The filing shows 31,337 shares were disposed at a price of $24.33; the filing explains those shares were forfeited to cover withholding taxes from the delivery of vested restricted stock units that settled on that date. Following the reported transaction, the filing records 59,446 shares beneficially owned by Mr. Shafer. The filing also notes automatic reinvestment of dividends is included in the total. The form is signed by an attorney-in-fact on behalf of Mr. Shafer.
FAQ
What is the current stock price of Baxter Intl (BAX)?
What is the market cap of Baxter Intl (BAX)?
